Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran
Tóm tắt
Từ khóa
Tài liệu tham khảo
Gibson A, Degenhardt L, Topp L, Day C, Hall W, Dietze P, McKetin R: Global and Australian heroin markets. 2003, Sydney, National Drug and Alcohol Research Centre, University of New South Wales
Reid G, Costigan G: Revisiting the Hidden Epidemic: A situation assessment of drug use in Asia in the context of HIV/AIDS. 2002, Melbourne, Centre for Harm Reduction, The Burnet Institute
Darke S, Zador D: Fatal heroin 'overdose': a review. Addiction. 1996, 91: 1765-1772. 10.1111/j.1360-0443.1996.tb03800.x.
Warner-Smith M, Darke S, Day C: Morbidity associated with non-fatal heroin overdose. Addiction. 2002, 97: 963-967. 10.1046/j.1360-0443.2002.00132.x.
Gossop M, Griffiths P, Powis B, Strang J: Severity of dependence and route of administration of heroin, cocaine and amphetamines. British Journal of Addiction. 1992, 87: 1527-1536. 10.1111/j.1360-0443.1992.tb02660.x.
Kaldor JM, Dore GJ, Correll PKL: Public health challenges in hepatitis C virus infection. Journal of Gastroenterology and Hepatology. 2000, 15 (Suppl): E83-E90. 10.1046/j.1440-1746.2000.02134.x.
Des Jarlais D, Hagan H, Friedman SR, Friedman P, Goldberg D, Frischer M, Green S, Tunving K, Ljungberg B, Wodak A, Ross M, Purchase D, Millson ME, Myers T: Maintaining low HIV seroprevalence in populations of Injecting drug users. Journal of the American Medical Association. 1995, 274: 1226-1231. 10.1001/jama.274.15.1226.
Friedman SR, Des Jarlais D: HIV among drug injectors: the epidemic and the response. AIDS Care. 1991, 3: 239-250.
Ray Kim W: Global epidemiology and burden of hepatitis C. Microbes and Infection. 2002, 4: 1219-1225. 10.1016/S1286-4579(02)01649-0.
Alavian SM, Gholami B, Masarrat S: Hepatitis C risk factors in Iranian volunteer blood donors: a case-control study. Journal of Gastroenterology and Hepatology. 2002, 17: 1092-1097. 10.1046/j.1440-1746.2002.02843.x.
Khani M, Vakili MM: Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Zanjan prisoners. Archives of Iranian Medicine. 2003, 6: 1-4.
Ahmadi J: Buprenorphine maintenance treatment of heroin dependence: the first experience from Iran. Journal of Substance Abuse Treatment. 2002, 22: 157-159. 10.1016/S0740-5472(02)00222-2.
Barnard MA: Needle sharing in context: patterns of sharing among men and women injectors and HIV risks. Addiction. 1993, 88: 805-812. 10.1111/j.1360-0443.1993.tb02094.x.
Swift W, Copeland J: Treatment needs and experience of Australian women with alcohol and other drug problems. Drug and Alcohol Dependence. 1996, 40: 211-219. 10.1016/0376-8716(95)01209-5.
Ahmadi J: A controlled trial of buprenorphine treatment for opium dependence: The first experience from Iran. Journal of Substance Abuse Treatment. 2002, 66: 111-114.
Ahmadi J, Bahrami N: Buprenorphine treatment of opium-dependent outpatients seeking treatment in Iran. Journal of Substance Abuse Treatment. 2002, 23: 415-417. 10.1016/S0740-5472(02)00272-6.
Hurley S, Jolley DJ, Kaldor JM: Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet. 1997, 349: 1797-1800. 10.1016/S0140-6736(96)11380-5.
MacDonald M, Law M, Kaldor J, Hales J, Dore GJ: Effectiveness of needle and syringe programmes for preventing HIV transmission. International Journal of Drug Policy. 2003, 14: 353-357. 10.1016/S0955-3959(03)00133-6.
Crofts N, Webb-Pullman J, Dolan K: An analysis of trends over time in social and behavioural factors related to the transmission of HIV among Injecting drug users and prison inmates. 1996, Canberra, Commonwealth Department of Health and Family Services
MacDonald MA, Wodak AD, Dolan KA, van Beek I, Cunningham PH, Kaldor JM: Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Medical Journal of Australia. 2000, 172: 57-61.
Dolan K: AIDS, drugs and risk behaviour in prison: state of the art. Harm Reduction in Prison. Edited by: Nedles J and Fuhrer A. 1997, Bern, Peter Lang, 213-238.
Dolan KA: Can Hepatitis C transmission be reduced in Australian prisons?. Medical Journal of Australia. 2001, 174: 378-379.
Rahbar AR, Rooholamini S, Khoshnood K: Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. International Journal of Drug Policy. 2004, 15: 151-155. 10.1016/j.drugpo.2003.07.001.
Dolan K, Shearer J, MacDonald M, Mattick R, Hall W, Wodak A: A randomised controlled trial of methadone maintenance treatment versus waitlist control in and Australian prison system. Drug and Alcohol Dependence. 2003, 72: 59-65. 10.1016/S0376-8716(03)00187-X.
Suligoi B, Magliochetti N, Nicoletti G, Pezzotti P, Rezza G: Trends in HIV Prevalence among Drug-Users Attending Public Drug-Treatment Centres in Italy: 1990-2000. Journal of Medical Virology. 2004, 73: 1-6. 10.1002/jmv.20054.
van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM: Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. British Medical Journal. 1998, 317: 433-437.
Brown TG, Topp J, Ross D: Rationales, obstacles and strategies for local outcome monitoring systems in substance abuse treatment settings. Journal of Substance Abuse Treatment. 2003, 24: 31-42. 10.1016/S0740-5472(02)00342-2.
Byrne A, Wodak A: Census of patients receiving methadone treatment in a general practice. Addiction Research. 1996, 3: 341-349.